Asal Pilehvari
Overview
Explore the profile of Asal Pilehvari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
19
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pilehvari A, You W, Kimmick G, Camacho F, Bonilla G, Anderson R
Clin Drug Investig
. 2025 Jan;
45(2):59-68.
PMID: 39797932
Background And Objective: Cyclin-dependent kinase (CDK)4/6 inhibitors in combination with endocrine therapy (ET) significantly enhance progression-free survival and overall survival in patients diagnosed with HR+/HER2- metastatic breast cancer (MBC). However,...
2.
Pilehvari A, You W, Kimmick G, Bonilla G, Anderson R
Breast Cancer Res Treat
. 2025 Jan;
PMID: 39762708
Purpose: While previous research has highlighted treatment delay inequities in early-stage breast cancer and identified potential contributing factors, there is limited research on disparities in treatment delays for metastatic breast...
3.
Pilehvari A, Chipoletti A, Krukowski R, Little M
BMC Pregnancy Childbirth
. 2024 Dec;
24(1):828.
PMID: 39702043
Background: Maternal smoking during pregnancy carries significant health risks for both mothers and infants, especially in vulnerable regions like rural and Appalachian areas with high smoking rates. Understanding the causes...
4.
Little M, Polaskey K, Pilehvari A, Krukowski R, Ribisl K, Pearce T
JAMA Netw Open
. 2024 Dec;
7(12):e2451517.
PMID: 39688869
No abstract available.
5.
Pilehvari A, Kimmick G, You W, Bonilla G, Anderson R
Breast Cancer Res
. 2024 Oct;
26(1):144.
PMID: 39425174
Objective: This study used real-world observational data to compare profiles of patients receiving different first-line treatment for hormone receptor positive (ER+), HER2 negative, metastatic breast cancer (MBC): CDK4/6 inhibitors (CDK4/6i)...
6.
Burris J, Feather A, Pilehvari A, Cooper S, Ashcraft A, Anderson R, et al.
Am J Prev Med
. 2024 Sep;
68(2):396-401.
PMID: 39343324
Introduction: Healthcare providers should facilitate smoking cessation, and primary care is an ideal setting for delivering this evidence-based care. This study's objective was to describe readiness to quit smoking combustible...
7.
Pilehvari A, You W, Grim S, Kessler R, Thomas J
Telemed J E Health
. 2024 Jul;
30(11):2682-2688.
PMID: 39072691
Electronic consultations (e-consults) provide a strategic solution to address challenges in health care systems related to cost management and access to care. This study aims to investigate the multilevel patient...
8.
Pilehvari A, Krukowski R, You W, Wiseman K, Wester A, Cohn W, et al.
J Rural Health
. 2024 Jul;
41(1):e12860.
PMID: 39031708
Purpose: Mitigating tobacco-related disparities in the Appalachian region and rural areas is crucial. This study seeks to gauge cigarette smoking prevalence in Virginia counties, uncover rurality and Appalachian-linked disparities, and...
9.
Kimmick G, Pilehvari A, You W, Bonilla G, Anderson R
Breast Cancer Res Treat
. 2024 Jun;
208(2):263-273.
PMID: 38922546
Purpose: To compare CDK4/6 inhibitor (CDK4/6i) with endocrine therapy (ET) in the first- versus second-line setting for treatment of hormone receptor positive (HR+), HER2 negative, metastatic breast cancer (MBC) using...
10.
Pilehvari A, Krukowski R, Wiseman K, Little M
Prev Med Rep
. 2024 May;
42:102716.
PMID: 38707246
Introduction: While cigarette smoking rates have declined, rural and Appalachian populations in the United States have not seen similar decreases. Quitline programs are promising strategies in reducing disparities in these...